398456-85-4

Upstream product

• 104-81-4 4-Methylbenzyl bromide 
• 7440-66-6 zinc 

Downstream Products

• 232602-11-8 2-(4-methyl-benzyl)-nicotinic acid methyl ester 
• 4412-50-4 2-(4-methylbenzyl)-1,3-dioxolane 
• 58358-54-6 (E,E)-4-methyl-4'-(4''-methylstyryl)stilbene 
• 881687-24-7 tert-butyl-2-{[4-({(2-furylmethyl)[6-(4-methylbenzyl)pyrimidin-4-yl]amino}methyl)phenyl]thio}-2-methylpropanoate 
• 1131428-75-5 3-(4-methylbenzyl)androsta-3,5-dien-17-ol 
• 1131428-73-3 3-(4-methylbenzyl)androsta-3,5-dien-17-yl acetate 
• 1131428-53-9 6-(4-methylbenzyl)androsta-4,6-diene-3,17-dione 
• 72685-34-8 3,3-dimethyl-2-(4-methylphenyl)methyl-1-butene 
• 1243000-27-2 (E)-4-(4-methylphenyl)methyl-4-octene 
• 1510826-48-8 N,N-dibenzyl-2-(9-benzyl-9H-purin-6-yl)-4-p-tolylbutanamide 
• 538-39-6 1,2-di-p-tolylethane 
• 16766-53-3 α-<2H1>p-xylene 

Relevant academic research and scientific papers

Stereoselective approach to access 3-tert-Butyl-Dimethylsiloxy-2,6-Substituted piperidines through nucleophilic addition of N,O-acetals with organozinc reagents

An efficient approach to access chiral 3-tert-butyl-dimethylsiloxy 2,6-disubstituted 6-benzyl piperidines was developed through nucleophilic addition of N,O-acetals with organozinc reagents. A number of substituted benzyl zinc reagents could react with N,

Csp3-Csp3 Bond-Forming Reductive Elimination from Well-Defined Copper(III) Complexes

Carbon-carbon bond-forming reductive elimination from elusive organocopper(III) complexes has been considered the key step in many copper-catalyzed and organocuprate reactions. However, organocopper(III) complexes with well-defined structures that can undergo reductive elimination are extremely rare, especially for the formation of Csp3-Csp3 bonds. We report herein a general method for the synthesis of a series of [alkyl-CuIII-(CF3)3]- complexes, the structures of which have been unequivocally characterized by NMR spectroscopy, mass spectrometry, and X-ray crystal diffraction. At elevated temperature, these complexes undergo reductive elimination following first-order kinetics, forming alkyl-CF3 products with good yields (up to 91%). Both kinetic studies and DFT calculations indicate that the reductive elimination to form Csp3-CF3 bonds proceeds through a concerted transition state, with a ΔH? = 20 kcal/mol barrier.

Novel preparation of N-arylmethyl-N-arylmethyleneamine N-oxides from benzylic bromides with zinc and isobutyl nitrite

Treatment of benzylic bromides with Zn and LiCl, followed by the reaction with i-butyl nitrite gave N-arylmethyl-N-arylmethyleneamine N-oxides in moderate yields. The present reaction is a novel and simple method for the preparation of nitrones from benzylic bromides, although the yields are moderate.

Access to Functionalized Quaternary Stereocenters via the Copper-Catalyzed Conjugate Addition of Monoorganozinc Bromide Reagents Enabled by N, N-Dimethylacetamide

Monoorganozinc reagents, readily obtained from alkyl bromides, display excellent reactivity with β,β-disubstituted enones and TMSCl in the presence of Cu(I) and Cu(II) salts to synthesize a variety of cyclic functionalized β-quaternary ketones in 38-99% yields and 9:1-20:1 diastereoselectivities. The conjugate addition features a pronounced improvement in DMA using monoorganozinc bromide reagents. A simple one-pot protocol that harnesses in situ generated monoorganozinc reagents delivers comparable product yields.

Efficient and General Aerobic Oxidative Cross-Coupling of THIQs with Organozinc Reagents Catalyzed by CuCl2: Proof of a Radical Intermediate

A general new method for the highly concise synthesis of C-1-alkylated tetrahydroisoquinolines (THIQ) is reported. The CuCl2-catalyzed procedure is based on a coupling of nonfunctionalized THIQs with organozinc reagents under aerobic conditions. It proceeds in high yields and is broadly applicable to a wide range of substrates. It relies on a regioselective sp3 C-H bond activation allowing for an sp3-sp3 bond union under mild reaction conditions in a rapid and effective manner. Mechanistically it involves an iminium ion intermediate that is formed via an organic radical involving a single-electron-transfer process. For the first time for this type of reaction a radical intermediate has been proven by EPR spectroscopy.

Highly regioselective three-component domino heck-negishi coupling reaction for the functionalization of purines at C6

A highly regioselective three-component domino Heck-Negishi coupling reaction has been developed. Organozinc reagents are used to trap an alkylpalladium intermediate of olefins for a first example in the domino Heck reaction. This reaction is applicable t

The synthesis of 1,2-diarylindenes via DDQ-mediated dehydrogenative intramolecular cyclization

A direct DDQ-mediated dehydrogenative intramolecular cyclization of (Z)-1,2,3-triaryl substituted propylenes promoted by Cu(OAc)2 was developed, providing 1,2-diarylindene derivatives in moderate to good yields (up to 92%) under mild conditions

Radical migration-addition of N-tert-butanesulfinyl imines with organozinc reagents

A novel migration-addition sequence was discovered for the reaction of enantioenriched N-tert-butanesulfinyl iminoacetate 1a with functionalized benzylzinc bromide reagents, producing tert-leucine derivatives in excellent diastereoselectivity (dr 98:2). The absolute configurations of two new chiral centers were unambiguously assigned by chemical transformations and X-ray crystallography. In addition, the regio- and diastereoselectivities of this novel reaction were both explained through the key N-sulfinamine intermediate M6 generated by the tert-butyl radical attack on the imine. Computational analysis of this reaction process, which was performed at the B3LYP/6-311++G(3df,2p)//B3LYP/6-31G-LANL2DZ level, also supported our proposed two-stage mechanism.

NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE AS PPAR-ALPHA MODULATORS

The invention relates to novel pyrimidine derivatives of general formula (I), methods for the production thereof, their use for treating and/or preventing diseases, and to their use for producing medicaments for treating and/or preventing diseases, preferably for treating and/or preventing cardiovascular diseases, particularly dyslipidemia, arteriosclerosis, insufficiency of the heart, thrombosis and metabolic syndrome.